Ascentage Pharma Group InternationalAAPG
Key ratios
FCF / Sales
-208.9%TTM
2025
-209.3%2024
-13.8%2023
-347.9%
Net margin
-228.5%TTM
2025
-216.5%2024
-41.3%
ROA
-28.0%TTM
2025
-23.0%2024
-9.3%2023
-20.9%
ROE
-236.6%TTM
2025
-154.6%2024
-235.3%2023
-386.3%
Revenue growth
64.5%TTM
2025
-41.5%2024
341.8%2023
5.9%
Recent news
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
Ascentage Pharma Appoints Dr. Faical Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
Track AAPG in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer